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CYP2C8*3 increases risk of neuropathy in breast
cancer patients treated with paclitaxel†
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Background: Paclitaxel-induced neuropathy is an adverse event that often leads to therapeutic disruption and patient
discomfort. We attempted to replicate a previously reported association between increased neuropathy risk and
CYP2C8*3 genotype.
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Patients and methods: Demographic, treatment, and toxicity data were collected for paclitaxel-treated breast
cancer patients who were genotyped for the CYP2C8*3 K399R (rs10509681) variant. A log-rank test was used in the
primary analysis of European-American patients. An additional independent replication was then attempted in a cohort
of African-American patients, followed by modeling of the entire patient cohort with relevant covariates.
Results: In the primary analysis of 209 European patients, there was an increased risk of paclitaxel-induced
neuropathy related to CYP2C8*3 status [HR (per allele) = 1.93 (95% CI: 1.05–3.55), overall log-rank P = 0.006]. The
association was replicated in direction and magnitude of effect in 107 African-American patients (P = 0.043). In the Cox
model using the entire mixed-race cohort (n = 411), each CYP2C8*3 allele approximately doubled the patient’s risk of
grade 2+ neuropathy (P = 0.004), and non-Europeans were at higher neuropathy risk than Europeans of similar
genotype (P = 0.030).
Conclusions: The increased risk of paclitaxel-induced neuropathy in patients who carry the CYP2C8*3 variant was
replicated in two racially distinct patient cohorts.
Key words: chemotherapy-induced peripheral neuropathy, cytochrome P450 2C8*3, paclitaxel, pharmacogenetics, race
introduction
Paclitaxel is one of the most highly effective therapies in the
treatment of breast cancer, improving disease-free survival when
added sequentially to anthracycline-based combination therapy
in the adjuvant setting [1]. Many patients, however, are unable
to tolerate the full course of paclitaxel therapy due to the
appearance and progression of sensory neurotoxicity. In large
trials, the rate of grade 2 or higher (grade 2+) and grade 3 or
higher (grade 3+) sensory neuropathy is 15%–20% and 5%–
10%, respectively [2, 3]. Sensory neuropathy typically manifests
as a tingling or burning sensation in the extremities that may
progress to loss of function that can be irreversible if treatment
is continued [4]; thus, paclitaxel therapy is often discontinued
once a patient experiences grade 2+ neurotoxicity.
There are known risk factors for the development of
paclitaxel-induced neuropathy. Patients who have prior
neuropathy, either from diabetes [5] or neurotoxic
chemotherapeutic treatment [6], or patients who are older [7]
or African American [8], have been reported to be at increased
risk. The progressive nature of paclitaxel-induced neuropathy
suggests toxicity development may be attributed to cumulative
drug exposure. Indeed, increased cumulative dose [9] and an
increase in the time that the drug concentration remains above
a threshold for a given dose [10] are both associated with
increased neuropathy risk.
Paclitaxel is primarily metabolized by CYP2C8 [11], with a
contribution from CYP3A4 [12], and exposure to paclitaxel in
cancer patients is correlated with CYP2C8 activity [13]. Thus,
any factor which modulates CYP2C8 activity is likely to
influence paclitaxel exposure, which is highly variable between
patients even after accounting for baseline factors such as body
size and bilirubin [14]. CYP2C8 has few known inhibitors and
inducers, limiting concerns for typical drug interaction.
However, single-nucleotide polymorphisms (SNPs) in the
CYP2C8 gene, such as the *3 (rs11572080 R139K and
rs10509681 K399R) variant, have decreased paclitaxel metabolic
activity [15] leading to increased drug exposure [16]. Based on
data from the International HapMap Project, the *3 variant is
more common in Caucasian individuals [Utah residents with
northern and western European ancestry (CEU) allele frequency
(AF) = 0.14] than African Americans [African Ancestry in
Southwest United States (ASW) AF = 0.04] [17, 18].
Gréen et al. [19] were the first to suggest a potential increase
in neuropathy risk for patients who carried the CYP2C8*3
variant. We recently reported results from a small
pharmacogenetic study demonstrating that breast cancer
patients treated with neoadjuvant paclitaxel who were carriers
of the *3 allele were more likely to achieve clinical complete
response from paclitaxel treatment (55% versus 23%;
OR = 3.92, 95% CI: 1.46–10.48, corrected P = 0.046), but tended
to have higher incidence of grade 3+ neuropathy (22% versus
8%; OR = 3.13, 95% CI: 0.89–11.01, uncorrected P = 0.075)
[20]. Leskela et al. [21] also reported a significant increase in
neuropathy risk for patients who were homozygous for the *3
allele. Therefore, we hypothesized that the increase in
neuropathy risk associated with CYP2C8*3 could be replicated
separately in independent cohorts of European-American and
African-American breast cancer patients treated with paclitaxel.
materials and methods
patients and treatments
CYP2C8*3 K399R (referred to as CYP2C8*3 from now on) was genotyped
in a cohort of patients treated between 2005 and 2011 and derived from the
University of North Carolina Lineberger Comprehensive Cancer Center
Breast Cancer Database, which collects patient data, including self-reported
race, treatment details, and toxic effects. Eligible women received
neoadjuvant and/or adjuvant paclitaxel-containing regimens and enrolled
in an IRB-approved clinical trial that collected genomic DNA from all
newly diagnosed patients. In most cases, patients received paclitaxel on a
standard neoadjuvant or adjuvant treatment regimen, with a predefined
dose, schedule, and duration. Some patients received additional biologic
treatment concurrent with paclitaxel, most commonly HER2-targeted
therapy for the subset of HER2-overexpressing tumors. Neuropathy
descriptions were recorded in the patient record based on clinician
judgment and patient reported symptoms. A study coordinator blinded to
patient genotype translated the physician description to a grade based on
National Cancer Institute Common Terminology Criteria for Adverse
Events [22]. Use of supplemental neuropathy prevention (glutamine,
vitamin B complex, or vitamin B6) or treatment (gabapentin or
amitriptyline) was at the discretion of the treating clinician. All patients
signed informed consent to participate and agreed to allow DNA to be
collected for additional pharmacogenetic studies. This study adhered to the
declaration of Helsinki and the study protocol was approved by the UNC
Institutional Review Board.
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SNP genotyping
A 30 ml blood sample was collected from each subject at the time of study
enrollment. DNA used for genotyping was extracted by the UNC
BioSpecimen Processing Facility and plated at 60 ng/µl. Genotyping was
carried out blinded to clinical data using the Affymetrix DMET™ Plus
Chip (Affymetrix, Inc., Santa Clara, CA) at Gentris Corporation (Gentris
Corporation, Morrisville, NC) following the manufacturer’s protocol with
known genomic DNA controls provided by Affymetrix to monitor inter-
and intra-assay performance. Any sample with call rate <98% was excluded
from analysis. CYP2C8*3 K399R (rs10509681) (AM_10125) was the only
SNP analyzed for this replication study; all non-*3 loci are assumed to be
wild-type (*1), enabling classification of each subject as CYP2C8
homozygous variant (*3/*3), heterozygous (*1/*3), or homozygous
wild-type (*1/*1).
statistical analysis
The primary analysis was carried out in a cohort of self-reported
European-American patients who were not analyzed in the previous
neoadjuvant study [20]. African-American patients were analyzed
separately in a cross-race replication. These two groups were then
combined with patients of other races and previously reported patients to
create a large mixed-race cohort. CYP2C8*3 genotype frequencies were
assessed for concordance with expectations under Hardy–Weinberg
equilibrium (HWE), using Fisher’s exact test. The primary toxicity end
point was the cumulative paclitaxel dose at which grade 2 or higher (grade
2+) neuropathy was first reported; any patient not experiencing grade 2+
toxicity was censored at their cumulative dose received. The primary
analysis plan was to use the log-rank test to determine whether there is a
difference in risk of grade 2+ neuropathy across European-American
patients classified by the CYP2C8*3 genotype. A standard α = 0.05 was
utilized due to the single SNP–phenotype association tested in the primary
analysis.
Following log-rank analysis, additional covariates [age (continuous
variable), prior diagnosis of diabetes (yes versus no), taxane schedule
(80–90 mg/m2 weekly versus 175 mg/m2 every 2 or 3 weeks), use of
prophylactic or therapeutic neuropathy treatment (yes versus no)] were
included in a multiple Cox proportional hazards model with CYP2C8*3
genotype assuming an additive genetic effect. Backward elimination using
the Akaike information criterion (AIC) was used to select the final model.
AIC balances model goodness of fit and complexity by penalizing the
inclusion of extra covariates; it has been shown to be an effective model
selection tool [23]. An additional replication of the positive findings in the
European-American cohort was attempted via log-rank analysis in the self-
reported African-American patients. Finally, the entire patient cohort was
analyzed in a multiple Cox proportional hazards model which included
self-reported race (European-American versus Non-European-American)
in addition to the previously described covariates. All statistical analyses
were carried out in the R statistical software, version 2.13.0 (R
Development Core Team, Vienna, Austria).
results
patient population
A total of 411 paclitaxel-treated patients were eligible for
analysis and successfully genotyped for CYP2C8*3 by
DMET™ Plus. Demographic data including patient and
treatment characteristics for the European-American (n = 209),
African-American (n = 107), and the combined mixed-race
cohort (n = 411) can be found in Table 1.
CYP2C8*3 K399R
The distribution of the CYP2C8*3 variant conformed to
HWE separately in the European-American (P = 0.79) and
African-American (P = 0.77) cohorts [24]. Allele frequencies in
the European-American (AF = 0.14) and African-American
(AF = 0.03) patients were consistent with that previously
reported for each reference population in the International
HapMap Project: CEU AF = 0.14 and ASWAF = 0.04 [17, 18].
The number of *1/*1, *1/*3, and *3/*3 women in each cohort
is displayed in Table 1 along with the frequency of grade 2+
neuropathy (17%–21%), which was similar to that reported in
prior paclitaxel studies.
neuropathy by genotype
analysis in European-American cohort
In the primary analysis of the European-American cohort, the
log-rank test demonstrated a difference in risk of grade 2+
neuropathy across genotype groups, as displayed in the
inverted Kaplan–Meier curves in Figure 1. As expected, risk of
neuropathy was highest in patients who were homozygous for
the *3 variant and lowest in patients homozygous for the wild-
type allele (log-rank P = 0.006). Assuming an additive genetic
effect, each variant allele a patient carried (0, 1, or 2)
approximately doubled their neuropathy risk [HR (per
allele) = 1.93, 95% CI: 1.05–3.55, P = 0.032].
Clinically relevant covariates (age, prior diabetes diagnosis,
use of neuropathy prophylaxis or treatment, and paclitaxel
schedule) were included in a multiple Cox proportional
hazards model. The only covariate that was kept in the
backwards selection procedure was diabetes history, which
increased neuropathy risk as expected (Table 2). Similar to the
unadjusted analysis, in the final model the association between
CYP2C8*3 genotype and risk of grade 2+ neuropathy was
significant [HR (per allele) = 1.95, 95% CI: 1.06–3.58,
P = 0.031].
replication in African-American cohort
A total of 107 self-reported African-American individuals were
assessable in the cross-race replication. As expected, the variant
allele was substantially less common in this cohort (AF = 0.03)
and there were no *3 homozygous individuals. Patients
carrying one CYP2C8*3 allele had greater neuropathy risk than
wild-type homozygous patients in the log-rank analysis
(HR = 3.30, 95% CI: 1.04–10.45, P = 0.043) (Figure 2).
Cox proportional hazards model in a mixed-race cohort
A total of 411 paclitaxel-treated women were assessable in a
Cox proportional hazards model that included self-reported
race (European-American versus non-European-American). In
the final model, the association between increased risk of grade
2+ neuropathy and CYP2C8*3 was significant [HR (per
allele) = 1.98, 95% CI: 1.25–3.13, P = 0.004] (Figure 3). There
was also a higher risk of grade 2+ neuropathy in non-European
women (HR = 1.76, 95% CI: 1.06–2.93, P = 0.030) (Figure 4)
and a non-significant, negligible influence of patient age
(HR = 1.00, 95% CI: 1.00–1.04, P = 0.102), but not of the other
covariates, including diabetes (Table 2).
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discussion
CYP2C8*3 has previously been implicated as a potential risk
factor for paclitaxel-induced peripheral neuropathy [20, 21].
The current study, which analyzed a single candidate SNP in a
large cohort of patients, had adequate statistical power to
determine the effect of CYP2C8*3, and other potentially
relevant clinical covariates, on neuropathy risk. We successfully
replicated an association between the CYP2C8*3 K399R
Table 1. Characteristics of patient cohorts: European-American cohort (n = 209), African-American cohort (n = 107), and the entire mixed-race cohort
(n = 411)
European-American (n = 209) African-American (n = 107) Mixed-race (n = 411)
Age (years)
Median 51 46 50
Range 24–84 25–68 22–84
Self-reported race
European 209 0 287 (70%)
African-American 0 107 107 (26%)
Other 0 0 17 (4%)
Neuropathy
Grade 2+ 35 (17%) 23 (21%) 76 (18%)
CYP2C8*3 (K399R) genotypea
Wild-type (*1/*1) 155 (74%) 101 (94%) 330 (80%)
Heterozygous (*1/*3) 51 (24%) 6 (6%) 76 (18%)
Variant (*3/*3) 3 (1%) 0 5 (1%)
Treatment before paclitaxel
AC (doxorubicin/cyclophosphamide) 154 (74%) 87 (81%) 316 (77%)
AC + bevacizumab 2 0 2
A (doxorubicin) 2 0 2
AC + docetaxel 1 0 1
None 50 (24%) 20 (19%) 90 (22%)
Treatment concurrent to paclitaxel
Trastuzumab 33 (16%) 21 (20%) 71 (17%)
Bevacizumab 4 (2%) 4 (4%) 9 (2%)
Carboplatin 1 1 2
Carboplatin + bevacizumab 1 2 3
Trastuzumab + lapatinib 4 0 4
Trastuzumab + cyclophosphamide 0 0 1
None 166 (79%) 79 (74%) 321 (78%)
Paclitaxel schedule and dose
80–90 mg/m2 weekly 64 (31%) 34 (32%) 131 (32%)
175 mg/m2 every 2 weeks 130 (62%) 64 (60%) 235 (57%)
175 mg/m2 every 3 weeks 15 (7%) 9 (8%) 45 (11%)
Total paclitaxel received
Median (mg/m2) 700 700 700
Range (mg/m2) 80–1280 160–1280 80–1280
Diabetes
Prior diagnosis 16 (8%) 24 (22%) 48 (12%)
No prior diagnosis 193 (92%) 83 (78%) 363 (88%)
Neuropathy prophylaxis or treatment
Gabapentin 6 (3%) 7 (7%) 15 (4%)
Amitriptyline 5 (2%) 1 9 (2%)
Glutamine 62 (30%) 22 (21%) 112 (27%)
Vitamin B complex 1 0 1
Vitamin B6 4 (2%) 2 7 (2%)
Total 78 (37%) 32 (30%) 144 (35%)
Treatment modalityb
Neoadjuvant 58 (28%) 47 (44%) 188 (46%)
Adjuvant 153 (73%) 61 (57%) 226 (55%)
Counts and percentages (in parentheses) are presented for categorical data. Medians and ranges are presented for quantitative data.
aDifferences expected due to cohort composition and known differences in allele frequency between races.
bTwo patients in the European-American and one in the African-American cohort were treated with paclitaxel neoadjuvantly and adjuvantly.
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(rs10509681) variant and increased risk of grade 2+ paclitaxel-
induced neuropathy in both European-American and African-
American patient cohorts. Finally, a model was built that
included all patients and relevant clinical covariates, and after
adjusting for age and race, the risk of grade 2+ neuropathy
approximately doubled for each CYP2C8*3 allele a patient
carried.
The prior report of an association between CYP2C8*3 and
paclitaxel-induced neuropathy from Leskela et al. was carried
out in a cohort of Spanish paclitaxel-treated cancer patients.
Using a similar analysis plan, end point, and covariates, the
current study confirmed the impact of CYP2C8*3 in a larger
cohort with robust statistical power (n = 411 versus n = 118).
An important aspect that differentiates this study from that of
Leskela et al. [21] and most other pharmacogenetic studies is
the single genotype–phenotype association that was selected a
priori for analysis. The vast majority of pharmacogenetic
studies are hypothesis-generating, discovery phase studies with
multiple variants and clinical end points tested. Based on data
from our group and others, this study exclusively tested the
hypothesis that the CYP2C8*3 variant increases risk of
paclitaxel-induced neuropathy. Confirming this hypothesis in
two patient cohorts that are independent from the discovery
cohort is strong evidence of the clinical validity of this
association [25].
Other attempts at demonstrating this association may have
suffered from suboptimal patient inclusion [26–29]. The study
from Rizzo et al. [26] combined patients on either paclitaxel
(24%) or docetaxel (76%) and analyzed these groups together.
While docetaxel has both structural and mechanistic
similarities with paclitaxel, it has a lower incidence of
neurotoxicity and is not metabolized by CYP2C8. The other
three studies utilized patient cohorts that were concomitantly
treated with the neuropathic agent carboplatin [30]. Systematic
concomitant treatment with another neurotoxic agent that is
not interacting with CYP2C8 could dilute the apparent
estimate of the effect of CYP2C8 genotype on neuropathy risk,
leading to false-negative findings. In the present study, all
patients were treated with paclitaxel and only six patients
(1.5%) were treated previously or concurrently with a
neuropathic chemotherapeutic agent (docetaxel or carboplatin)
(Table 1). Post hoc exclusion of these subjects for sensitivity
testing had a negligible influence on our results (data not
shown).
Based on HapMap reference populations, the *3 variant is
not found in patients of African descent [Yoruban in Ibadan,
Nigeria (YRI) AF = 0.00]. The AF in our African-American
patients (AF = 0.03) was consistent with that reported for
individuals of African ancestry living in the United States
(ASWAF = 0.04), likely reflecting the known admixture found
in African-American patients [31]. Based on our findings, not
only is the *3 variant found in individuals from a wide range
of self-reported races, the approximate doubling of neuropathy
risk it confers is consistent across racial groups.
Beyond CYP2C8 genotype, non-European individuals were
at an increased risk of neuropathy (HR = 1.76, 95%
CI: 1.05–2.93, P = 0.031), supporting a recent publication [8]
and a preliminary report [32] from two separate large clinical
trials of paclitaxel use in breast cancer patients. These findings
suggest that while CYP2C8*3 is one factor that influences a
patient’s risk of paclitaxel-induced neuropathy, perhaps along
with age and diabetes history, there are other currently
unappreciated factors at work. It is noteworthy that the risk of
HIV-associated distal neuropathy [33] and diabetes-related
neuropathy [34] is greater in African Americans than in
European Americans; thus, there seems to be a general
predisposition to neuropathy in African Americans irrespective
of etiology. We hypothesize that there are inter-race differences
in frequencies of genetic loci responsible for this phenotype.
Figure 1. Incidence curve for grade 2+ neuropathy across genotype groups
in the European-American cohort (n = 209). The highest risk was seen in
the variant homozygotes and the lowest risk in the wild-type homozygotes.
Table 2. Multiple Cox proportional hazards model for grade 2+ neuropathy in the European-American cohort (n = 209) and the entire mixed-race cohort
(n = 411)
European-American cohort (n = 209) Mixed-race cohort (n = 411)
Hazard ratio 95% confidence interval P-value Hazard ratio 95% confidence interval P-value
CYP2C8 additive genetic model 1.95 1.06–3.58 0.031a 1.98 1.25–3.13 0.004a
Diagnosis of diabetes 2.25 0.87–5.81 0.093 Excluded from final model
Age Excluded from final model 1.00 1.00–1.04 0.102
Self-reported raceb Not applicable 1.76 1.06–2.93 0.030a
CYP2C8*3 was assumed to have an additive genetic effect in which the estimated hazard ratio represents the increase in neuropathy risk per variant allele.
aStatistically significant.
bNon-European-American (African-American + other) versus European-American.
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The major limitation of this study is the retrospective use of
a clinical registry instead of a prospective clinical study. This
manifests in a number of ways, most notably the differences in
paclitaxel treatment and schedule, the use of neuropathy
prophylaxis or treatment, and the potential non-uniformity in
toxicity collection. We have attempted to adjust for these
factors where possible. In meta-analyses comparing the risk of
neuropathy for the weekly versus tri-weekly schedules, the dose
intensity was found to be a more important factor than
schedule itself [35]. The patients in this analysis were treated
with one of three standard paclitaxel regimens: 3-h infusion of
175 mg/m2 every 3 weeks (58.3 mg/m2/week) or every 2 weeks
(87.5 mg/m2/week) or a 1-h weekly infusion (80–90 mg/m2/
week). Despite attempts to include these data in Cox models,
we could not detect a significant influence on neuropathy risk
for paclitaxel dose, schedule, or infusion time, all of which are
highly collinear in this dataset.
In conclusion, we have replicated in two racially
homogenous populations our previous finding that
CYP2C8*3 carriers are more likely to experience peripheral
neuropathy when treated with paclitaxel. Analysis of the
influence of a single SNP (CYP2C8*3) on the risk of a
defined adverse event (grade 2+ neuropathy) in a large
cohort of paclitaxel-treated patients enabled a definitive
assessment of this association, which remained significant
after adjustment for clinical covariates that are thought to
modify risk of neuropathy. In our mixed-race cohort, the risk
of neuropathy approximately doubled for each *3 variant a
patient carried, indicating a clear additive or gene-dose effect
(Figure 3). Patients who are known to carry CYP2C8*3, and
particularly those known to be homozygous, should be
assumed to be at increased risk of peripheral neuropathy
during paclitaxel treatment. Additional work is needed to
translate these findings to clinical practice, such as a
genotype-guided dosing study. A prospective study could
demonstrate the clinical utility of individualizing paclitaxel
therapy based on CYP2C8 genotype, enabling optimization of
the risk/benefit profile of this essential chemotherapeutic
agent.
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